Table III.
Number (%) of Participants With Angioedema | |||||
---|---|---|---|---|---|
Time from Randomization to Onset of Angioedema | C | A | L | D | Total |
<1 d | 1 | 0 | 2 | 0 | 3 |
1–7 d | 1 | 0 | 6 | 2 | 9 |
Total within first wk† | 2 (25) | 0 | 8 (22) | 2 (40) | 12 (23) |
8–14 d | 0 | 0 | 1 | 0 | 1 |
15–30 d | 0 | 0 | 4 | 1 | 5 |
Total within first mo† | 2 (25) | 0 | 13 (35) | 3 (60) | 18 (34) |
31–60 d | 0 | 0 | 3 | 1 | 4 |
61–90 d | 0 | 1 | 2 | 0 | 3 |
Total within first 3 mo† | 2 (25) | 1 (33) | 18 (49) | 4 (80) | 25 (47) |
91–182 d | 0 | 1 | 3 | 0 | 4 |
6 mo–1 y | 0 | 1 | 6 | 1 | 7 |
Total within first year† | 2 (25) | 3 (100) | 27 (73) | 5 (100) | 36 (68) |
1–2 y | 0 | 0 | 3 | 0 | 4 |
>2–3y | 1 | 0 | 3 | 0 | 4 |
>3–4y | 3 | 0 | 2 | 0 | 5 |
>4–5y | 0 | 0 | 1 | 0 | 1 |
>5–6y | 1 | 0 | 1 | 0 | 2 |
>6 y | 0 | 1 | 0 | 0 | 1 |
ALLHAT indicates Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial; C, chlorthalidone; A, amlodipine; L, lisinopril; and D, doxazosin. *For participants who experienced more than one episode of angioedema, only the first is considered. †Values are cumulative. |